• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从大规模平行测序数据中检测马来西亚原住民的 CYP2C19 基因变异。

Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data.

机构信息

Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA Selangor (UiTM), Puncak Alam, Selangor, Malaysia.

Faculty of Pharmacy, Universiti Teknologi MARA Selangor (UiTM), Puncak Alam, Selangor, Malaysia.

出版信息

PLoS One. 2016 Oct 31;11(10):e0164169. doi: 10.1371/journal.pone.0164169. eCollection 2016.

DOI:10.1371/journal.pone.0164169
PMID:27798644
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5087908/
Abstract

The human cytochrome P450 (CYP) is a superfamily of enzymes that have been a focus in research for decades due to their prominent role in drug metabolism. CYP2C is one of the major subfamilies which metabolize more than 10% of all clinically used drugs. In the context of CYP2C19, several key genetic variations that alter the enzyme's activity have been identified and catalogued in the CYP allele nomenclature database. In this study, we investigated the presence of well-established variants as well as novel polymorphisms in the CYP2C19 gene of 62 Orang Asli from the Peninsular Malaysia. A total of 449 genetic variants were detected including 70 novel polymorphisms; 417 SNPs were located in introns, 23 in upstream, 7 in exons, and 2 in downstream regions. Five alleles and seven genotypes were inferred based on the polymorphisms that were found. Null alleles that were observed include CYP2C19*3 (6.5%), *2 (5.7%) and *35 (2.4%) whereas allele with increased function *17 was detected at a frequency of 4.8%. The normal metabolizer genotype was the most predominant (66.1%), followed by intermediate metabolizer (19.4%), rapid metabolizer (9.7%) and poor metabolizer (4.8%) genotypes. Findings from this study provide further insights into the CYP2C19 genetic profile of the Orang Asli as previously unreported variant alleles were detected through the use of massively parallel sequencing technology platform. The systematic and comprehensive analysis of CYP2C19 will allow uncharacterized variants that are present in the Orang Asli to be included in the genotyping panel in the future.

摘要

人类细胞色素 P450(CYP)是一个超级酶家族,由于其在药物代谢中的重要作用,几十年来一直是研究的焦点。CYP2C 是主要亚家族之一,代谢超过 10%的所有临床使用药物。在 CYP2C19 的背景下,已经确定并在 CYP 等位基因命名数据库中编目了几个改变酶活性的关键遗传变异。在这项研究中,我们研究了马来半岛 62 名原住民族 CYP2C19 基因中存在的既定变体和新的多态性。共检测到 449 种遗传变异,包括 70 种新的多态性;417 个 SNP 位于内含子中,23 个位于上游,7 个位于外显子中,2 个位于下游区域。根据发现的多态性推断出 5 个等位基因和 7 种基因型。观察到的无效等位基因包括 CYP2C193(6.5%)、2(5.7%)和35(2.4%),而功能增强的等位基因17 的频率为 4.8%。正常代谢基因型是最主要的(66.1%),其次是中间代谢基因型(19.4%)、快速代谢基因型(9.7%)和不良代谢基因型(4.8%)。这项研究的结果提供了更多关于原住民族 CYP2C19 遗传特征的信息,因为通过使用大规模平行测序技术平台检测到了以前未报告的变体等位基因。对 CYP2C19 的系统和全面分析将允许将目前在原住民族中存在的未表征变异纳入未来的基因分型面板中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5773/5087908/e3b07f3dd814/pone.0164169.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5773/5087908/e3b07f3dd814/pone.0164169.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5773/5087908/e3b07f3dd814/pone.0164169.g001.jpg

相似文献

1
Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data.从大规模平行测序数据中检测马来西亚原住民的 CYP2C19 基因变异。
PLoS One. 2016 Oct 31;11(10):e0164169. doi: 10.1371/journal.pone.0164169. eCollection 2016.
2
A study on the genetic polymorphisms of CYP3A5 among the Orang Asli in Malaysia using a next generation sequencing platform.一项使用下一代测序平台对马来西亚原住民奥朗阿斯利人CYP3A5基因多态性的研究。
Ann Hum Biol. 2018 Mar;45(2):166-169. doi: 10.1080/03014460.2018.1440004. Epub 2018 Feb 25.
3
Inference of the Genetic Polymorphisms of CYP2D6 in Six Subtribes of the Malaysian Orang Asli from Whole-Genome Sequencing Data.基于全基因组测序数据推断马来西亚原住民六个亚部落中CYP2D6基因的遗传多态性
Genet Test Mol Biomarkers. 2017 Jul;21(7):409-415. doi: 10.1089/gtmb.2016.0235. Epub 2017 May 19.
4
Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.中国汉族人群 CYP2C19 和 CYP2D6 的遗传多态性、连锁不平衡、单倍型结构和新等位基因分析。
Pharmacogenomics J. 2009 Dec;9(6):380-94. doi: 10.1038/tpj.2009.31. Epub 2009 Jul 28.
5
Systematic characterization and comparison of the CYP2C9 variability of the Orang Asli in Malaysia with 12 populations.马来西亚原住民Orang Asli的CYP2C9基因多态性与12个群体的系统特征分析及比较
Drug Metab Pharmacokinet. 2016 Aug;31(4):304-13. doi: 10.1016/j.dmpk.2016.04.004. Epub 2016 Apr 28.
6
Distribution of CYP2C19*17 allele and genotypes in an Indian population.CYP2C19*17 等位基因和基因型在印度人群中的分布。
J Clin Pharm Ther. 2012 Jun;37(3):313-8. doi: 10.1111/j.1365-2710.2011.01294.x. Epub 2011 Sep 15.
7
Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China.中国大陆不同地理区域汉族人群中CYP2C19的基因多态性分析
Pharmacogenomics. 2008 Jun;9(6):691-702. doi: 10.2217/14622416.9.6.691.
8
Population data for 15 autosomal STR loci in Orang Asli subgroups of Peninsular Malaysia.马来西亚半岛原住民各亚组中15个常染色体短串联重复序列(STR)位点的群体数据。
Int J Legal Med. 2022 Mar;136(2):547-549. doi: 10.1007/s00414-021-02718-5. Epub 2021 Oct 4.
9
Distribution of cytokine gene polymorphisms in six Orang Asli subgroups in Peninsular Malaysia.马来西亚半岛六个原住民亚组中细胞因子基因多态性的分布
Hum Immunol. 2016 Apr;77(4):338-9. doi: 10.1016/j.humimm.2016.01.015. Epub 2016 Jan 26.
10
[Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].[福建汉族人群中CYP2C19基因多态性与缺血性脑卒中远期复发风险的关联]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2015 Dec;32(6):871-6. doi: 10.3760/cma.j.issn.1003-9406.2015.06.026.

引用本文的文献

1
variability and clinical outcomes of clopidogrel, proton pump inhibitors, and voriconazole in Southeast Asia: a systematic review and meta-analysis.东南亚地区氯吡格雷、质子泵抑制剂和伏立康唑的变异性及临床结局:一项系统评价和荟萃分析。
Front Pharmacol. 2025 Jun 19;16:1572886. doi: 10.3389/fphar.2025.1572886. eCollection 2025.
2
The Diversity of Polymorphisms in the Thai Population: Implications for Precision Medicine.泰国人群中多态性的多样性:对精准医学的启示。
Appl Clin Genet. 2024 Jul 2;17:95-105. doi: 10.2147/TACG.S463965. eCollection 2024.
3
Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical Outcomes.

本文引用的文献

1
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).临床药物遗传学检测结果术语标准化:来自临床药物遗传学实施联盟(CPIC)的共识术语
Genet Med. 2017 Feb;19(2):215-223. doi: 10.1038/gim.2016.87. Epub 2016 Jul 21.
2
Ancient Genetic Signatures of Orang Asli Revealed by Killer Immunoglobulin-Like Receptor Gene Polymorphisms.杀伤细胞免疫球蛋白样受体基因多态性揭示的奥朗阿斯利人的古代遗传特征
PLoS One. 2015 Nov 13;10(11):e0141536. doi: 10.1371/journal.pone.0141536. eCollection 2015.
3
The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.
印度尼西亚的基因多态性:不同种族间的比较及其与临床结局的关联
Biology (Basel). 2021 Apr 6;10(4):300. doi: 10.3390/biology10040300.
4
Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications.药物遗传学研究中种族和民族分类的不一致性及其潜在的临床意义。
Pharmgenomics Pers Med. 2019 Jul 2;12:107-123. doi: 10.2147/PGPM.S207449. eCollection 2019.
5
Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers.单胺氧化酶A和细胞色素P450对健康志愿者中伯氨喹代谢的影响。
Parasitol Res. 2019 Mar;118(3):1011-1018. doi: 10.1007/s00436-019-06210-3. Epub 2019 Jan 31.
CYP2C19基因内含子2分支点单核苷酸多态性是导致携带CYP2C19*35和CYP2C19*2等位基因的肝脏中代谢不良表型的祖先多态性。
Drug Metab Dispos. 2015 Aug;43(8):1226-35. doi: 10.1124/dmd.115.064428. Epub 2015 May 28.
4
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.临床药物基因组学实施联盟(CPIC)关于CYP2D6和CYP2C19基因分型与选择性5-羟色胺再摄取抑制剂给药的指南。
Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29.
5
From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline.从FastQ数据到高可信度变异检测:基因组分析工具包最佳实践流程
Curr Protoc Bioinformatics. 2013;43(1110):11.10.1-11.10.33. doi: 10.1002/0471250953.bi1110s43.
6
Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.细胞色素 P450 酶的遗传差异与抗抑郁治疗反应。
J Psychopharmacol. 2014 Feb;28(2):133-41. doi: 10.1177/0269881113512041. Epub 2013 Nov 20.
7
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.临床药物遗传学实施联盟 CYP2C19 基因型和氯吡格雷治疗指南:2013 年更新。
Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
8
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.临床药物遗传学实施联盟指南:CYP2D6 和 CYP2C19 基因型与三环类抗抑郁药剂量
Clin Pharmacol Ther. 2013 May;93(5):402-8. doi: 10.1038/clpt.2013.2. Epub 2013 Jan 16.
9
Tailoring drug therapy based on genotype.基于基因型定制药物治疗。
J Pharm Pract. 2012 Aug;25(4):413-6. doi: 10.1177/0897190012448311.
10
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.PharmGKB 总结:细胞色素 P450、家族 2、亚家族 C、多肽 19 的重要药物基因信息。
Pharmacogenet Genomics. 2012 Feb;22(2):159-65. doi: 10.1097/FPC.0b013e32834d4962.